
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62 million. In Q4, Aligos Therapeutics brought in $367.00 thousand in sales but lost $37.71 million in earnings.